GT Spotlight: Establishing a new paradigm in heart valve treatment
Immense progress on Capstan Medical.
Read more ›
Immense progress on Capstan Medical.
Read more ›
With $31.4 million in new funding, the company will bring the benefits of robotics to one of the few remaining untouched areas of medicine, structural heart
Read more ›
Boundless Bio announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital. Boundless Bio will use the financing to advance BBI-355, the first ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers.
Read more ›